Directors bring expertise across healthcare access, medtech, commercial and manufacturing operations and public-company governance as MiniMed begins its next chapter as an independent company focused on making every day a better day for people with diabetes.

NORTHRIDGE, Calif., Oct. 15, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced the composition of its Board of Directors following the completion of the company's separation from Medtronic. This new Board composition reflects MiniMed's priorities as an independent public company, including focused growth, continued innovation, disciplined execution and broader access to diabetes technology. The Board's collective experience spans healthcare delivery and access, medical technology, manufacturing operations, corporate governance and consumer engagement.

Kevin E. Lofton remains as chair of the Board. Amy Bricker and Tim L. Main are joining the Board, effective immediately, as part of the planned transition from Medtronic-designated directors. Their appointments complete MiniMed's transition to its post-separation Board.

"As an independent public company, MiniMed has a clear mission: reduce the burden of diabetes management and make integrated technology easier to access and use," said Que Dallara, Chief Executive Officer of MiniMed. "That requires a Board that understands healthcare access and patient needs, and can also help us execute across technology, commercial operations, manufacturing, finance and governance. Our directors bring that range of experience as we build a simpler, more dependable experience for people with diabetes."

The new Board of Directors comprises nine members:

   -- Kevin E. Lofton, Chair -- Former Chief Executive Officer, CommonSpirit 
      Health: Lofton is the former CEO of CommonSpirit Health, one of the 
      largest health systems in the United States, formed through the 2019 
      merger of Catholic Health Initiatives (CHI) and Dignity Health. He 
      previously served for nearly two decades as CEO of CHI, leading its 
      significant growth and transformation, and held CEO roles at Howard 
      University Hospital and UAB Hospital. Lofton currently serves on the 
      Boards of Medtronic plc, Howard University and the Georgia State 
      University Foundation. He previously served on the Boards of Gilead 
      Sciences and Rite Aid. 
 
          -- Board Chair, Nominating & Corporate Governance and Compensation & 
             Talent Committees 
 
   -- Que Dallara -- Chief Executive Officer, MiniMed: Dallara has served as 
      CEO of MiniMed since March 2026. She was EVP & President of Medtronic 
      Diabetes since 2022, leading the company's return to growth and 
      separation from Medtronic and its Nasdaq listing in March 2026. She 
      brings more than two decades of global leadership experience across 
      healthcare, software, and manufacturing industries. Previously, she 
      served as President and CEO of Honeywell Connected Enterprise and Senior 
      Vice President and Chief Commercial Officer of Honeywell. Earlier in her 
      career, she held leadership roles at TE Connectivity, Microsoft, Telstra 
      and McKinsey & Company. Dallara also serves on the Board of Lattice 
      Semiconductor. 
 
   -- Amy Bricker --Executive Vice President, Enterprise Pharmacy, Walgreens; 
      Former President, Express Scripts: Bricker currently serves as Executive 
      Vice President, Enterprise Pharmacy at Walgreens, where she leads 
      community and specialty pharmacy strategy and operations. A pharmacist by 
      training, she brings more than 25 years of experience across pharmacy 
      benefit management, consumer healthcare, retail pharmacy and government 
      healthcare programs. Previously, she served as President of Express 
      Scripts, overseeing a business with more than $100 billion in annual 
      revenue serving more than 100 million covered lives. Bricker also served 
      as a Commissioner on the Medicare Payment Advisory Commission, advising 
      policymakers on healthcare reimbursement and pharmacy-related issues. 
 
          -- Nominating & Corporate Governance Committee 
 
   -- Glenn Eisenberg -- Former Executive Vice President and Chief Financial 
      Officer, Labcorp Holdings Inc.: Eisenberg is the former Executive Vice 
      President and CFO of Labcorp, where he served from 2014 to 2024. During 
      his tenure, he helped guide approximately 100 acquisitions representing 
      roughly $11 billion in investment. Previously, he served as Executive 
      Vice President and CFO of The Timken Company and held senior leadership 
      positions at United Dominion Industries, including President and Chief 
      Operating Officer. Eisenberg currently serves on the Boards of Solventum, 
      Lumexa Imaging and Middleby and has held director positions at several 
      other public companies. 
 
          -- Audit Committee Chair, Nominating & Corporate Governance Committee 
 
   -- David Endicott -- Chief Executive Officer, Alcon: Endicott has served as 
      CEO of Alcon since 2018 and as a member of its Board since 2019. He 
      joined Alcon as Chief Operating Officer in 2016 and led the company's 
      separation and return to the public markets. Previously, he served as 
      President of Hospira Infusion Systems, a Pfizer company, and spent more 
      than 25 years at Allergan in leadership roles across the United States, 
      Europe, Asia and Latin America. Endicott currently serves on the Board of 
      AdvaMed and previously served on the Boards of Zeltiq and Orexigen 
      Therapeutics. 
 
          -- Compensation & Talent Committee 
 
   -- Keith Grossman -- Former President and Chief Executive Officer, Nevro 
      Corp.: Grossman is the former President and CEO of Nevro Corp., where he 
      served from 2019 to 2023 before transitioning to Chairman of the Board. A 
      four-time public company CEO, he brings more than 35 years of medical 
      device leadership and extensive experience building and scaling 
      healthcare technology businesses. His previous leadership roles include 
      Thoratec Corporation, which was acquired by St. Jude Medical for $3.4 
      billion, Conceptus and Texas Pacific Group. Grossman currently serves as 
      Vice Chairman of Alcon and Chairman of Outset Medical and has held Board 
      positions at numerous public and private medical technology companies. 
 
          -- Nominating & Governance Committee Chair, Audit Committee 
 
   -- Bob Hopkins -- Senior Vice President and Head of Global Strategy, 
      Medtronic: Hopkins serves as Senior Vice President and Head of Global 
      Strategy at Medtronic, where he leads corporate strategy, with a 
      particular emphasis on capital allocation and portfolio oversight. He 
      brings more than 25 years of medical technology industry experience. 
      Prior to joining Medtronic in 2021, he served as Managing Director and 
      Senior Equity Research Analyst at Bank of America Merrill Lynch, covering 
      the medical technology sector. Earlier in his career, he held leadership 
      roles at Lehman Brothers and Donaldson, Lufkin & Jenrette. 
 
   -- Timothy L. Main -- Former Chief Executive Officer and Chairman, Jabil, 
      Inc.: Main is the former CEO and Chairman of Jabil, Inc., a global 
      electronic product solutions company. As CEO from 2000 to 2013, he led 
      Jabil's growth strategy, increasing annual revenue nearly fivefold to $17 
      billion and expanding operations across Asia and emerging markets. He 
      subsequently served as non-executive Chairman until 2021. Main also 
      served as Chairman of WNS Holdings Ltd. from 2021 until its sale in 2025. 
      He currently serves on the Board of Quest Diagnostics, where he has held 
      leadership roles across cybersecurity, governance, audit and finance 
      committees. 
 
          -- Audit and Compensation & Talent Committees 
 
   -- Timothy Wicks -- Former Executive Vice President and Chief Financial 
      Officer, Optum: Wicks is the former Executive Vice President and CFO of 
      Optum, where he held leadership responsibilities across Optum Financial, 
      Supply Chain and OptumRx during nearly 20 years with UnitedHealth Group. 
      His experience spans healthcare operations, product development, business 
      development and strategic partnerships. Wicks currently serves on the 
      Board of BrightSpring as well as the Board of Global Medical Response 
      $(GMRS)$. Wicks previously served on the Boards of Precision Castparts and 
      Aerojet Rocketdyne, including their finance and audit committees. 
 
          -- Compensation & Talent Committee Chair, Audit Committee 

The appointments are part of a broader governance and leadership transition as MiniMed establishes itself as an independent public company. MiniMed is entering this next chapter with a clear focus on connecting insulin delivery, glucose sensing, algorithms, software, clinical expertise and human support to create a simpler, more dependable experience for people with diabetes.

About MiniMed

MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.